homocysteine [Hcy] ) to define deficiency, the "screening" serum B 12 cutoff used in many diagnostic algorithms has been raised to 250 pg/mL to 300 pg/mL to provide greater sensitivity. 6 With this approach, the prevalence of vitamin B 12 deficiency may be as high as 15% to 20% in the elderly. 7 Of course, most of these patients will have no hematologic or neurologic manifestations of B 12 deficiency (ie, subclinical deficiency). 8 Holotranscobalamin (holoTC) has been reported to offer slightly better performance than total serum B 12 levels in diagnosing deficiency, but these study designs have been criticized, and there is currently no consensus that holoTC should replace conventional serum B 12 testing. 8, 9 Given the limitations of current testing for vitamin B 12 deficiency, and because its administration is inexpensive and fairly innocuous, many clinicians have a low threshold for prescribing vitamin B 12 supplementation (usually by intramuscular injection to bypass issues with absorption). However, this approach may give a false sense of effective medical intervention for both the patient and provider, thereby diverting attention away from further evaluation and appropriate diagnosis.
In recent years, a number of diagnostic algorithms for evaluating vitamin B 12 deficiency have been promulgated, but adherence to these recommendations in clinical practice is unknown. Also, how well these algorithms actually perform in terms of predicting meaningful response to vitamin B 12 supplementation is unclear. In this study, we sought to systematically evaluate current practice patterns regarding the laboratory evaluation of suspected vitamin B 12 deficiency.
Methods
This study was approved with waiver of written informed consent by the Institutional Review Board of Marshfield Clinic, a large, multi-specialty, multi-site group practice with regional centers throughout central and northern Wisconsin. Medical records of 250 potential subjects were electronically identified utilizing the Healthcare Common Procedure Coding System (HCPCS) code for vitamin B 12 injection (J3420) and International Classification of Diseases (ICD-9-CM) codes related to vitamin B 12 deficiency (266.2, 281.0-1), with 125 randomly selected for manual review from each of the calendar years 2000 and 2005. Fifty-eight patients were excluded, leaving 192 cases (93 from year 2000 and 99 from year 2005) that formed the basis for this study. Reasons for exclusion were previous vitamin B12 injections within 12 months before the reference date (26 cases), documented alcohol abuse (16 cases), undergoing chemotherapy or hormonal therapy for a malignancy (9 cases), and no documentation that vitamin B 12 therapy was initiated (7 cases). Very few patients had well-documented neurologic exams, which generally precluded objective evaluation of neurologic improvement. immunoassay incorporating intrinsic factor. The correlation between the two methods was: Access = 0.966 x (Immuno1) + 12; (n = 42 lab employees). Based on complaints from Marshfield Clinic neurologists regarding a longstanding history of referrals for low B 12 results, the lower limit of the reference range was changed at that time to 160 pg/mL.
Methylmalonic acid in serum was determined by liquid chromatography-tandem mass spectrometry using butanol derivatization with deuterated MMA as the internal standard on an Applied Biosystems API 3000 with Analyst 1.4 software. The reference range was 0.0-0.40 µmol/L. Plasma Hcy was assayed by an enzymatic method measuring S-adenosylmethionine catalyzed by homocysteine-Smethyltransferase. Our laboratory utilized age-adjusted reference ranges (eg, <16.5 for males 61-80 years and <14.8 for females 61-80 years).
Baseline patient data had to be within 6 months before initiation of intramuscular B 12 therapy. Follow-up data had to be at least 2 months after this date, but not more than 12 months. MCV data. Serum MMA was directly correlated with Cr: r = 0.33 (P=0.04). Only 88 patients had both baseline and follow-up B 12 levels assessed. As illustrated in figure 4 , B 12 levels rose for the vast majority of the patients in Groups 2, 3, and 4, providing laboratory evidence that supplementation was occurring. Follow-up B 12 levels were ≥100 pg/mL for all but one individual. A significantly greater number of patients had both baseline and follow-up Hgb and MCV assessed: 136 and 131, respectively. There were no significant correlations between the changes in these variables and the B12 increment (data not shown). In contrast, the change in MCV was significantly correlated with the baseline B 12 level (r = 0.27, P=0.003); this relationship is illustrated in figure 5 . Vertical lines at 100 pg/mL and 250 pg/mL indicate the cutoffs used for group assignment. Data points in the lower left quadrant represent patients in whom the baseline B 12 was <100 pg/mL, and MCV decreased as would be expected with a hematologic response to B 12 supplementation.
Remarkably, 35.4% of patients had no laboratory evidence to justify therapeutic intervention (Group 1), and another 46.3% had only possible B 12 deficiency (Group 2). Only two of these patients had a hematologic response. Notably, these two patients had the lowest baseline B 12 values of all the patients in either Group 1 or 2 (103 and 107 pg/mL).
Twenty-four patients had probable B 12 deficiency defined as a baseline B 12 <100 pg/mL without measuring MMA (Group 3). Eighteen of these had both baseline and follow-up Hgb and MCV data and are included in figure 5 . Eight patients met the criteria for hematologic response, and another four had equivocal hematologic responses (eg, incomplete data or changes not quite fulfilling those criteria.)
The one patient with a plausible neurologic response was in this group. She was a woman, age 68 years, in whom paresthesias of both feet had resolved when she was examined 6 weeks after initiation of B 12 therapy; criteria for hematologic response were not met.
Eleven patients had "confirmed" B 12 deficiency defined as a serum B 12 ≤250 and serum MMA >0.40 µmol/L (Group 4). All but one had baseline Hgb and MCV data, but just seven (shown in figure 5 ) had follow-up hematologic data. An interesting observation was that 37 patients (27 females and 10 males) had a history of gastrointestinal surgery that may have predisposed them to malabsorption of certain nutrients including vitamin B 12 . Of these surgical procedures, 24 were gastric bypass or gastrectomy (the vast majority for morbid obesity), and 20 of these patients were women. Of the thirty-five patients that had baseline serum B 12 levels, five were <100 pg/mL, 27 were between 100 pg/mL and 250 pg/mL, and three were >250 pg/mL. Only three patients had evidence of a hematologic response. 12 injections. In 10 patients this was well-documented, and it was strongly suspected in another six in whom there was incomplete laboratory documentation. In 13 of 15 patients with baseline B 12 levels, they were 250 pg/mL or below (ranging from 57 pg/ mL to 238 pg/mL). The highest MCV in an iron deficient patient was 90.5 fL; whereas, the lowest MCV in a patient with documented or equivocal clinical response to B 12 supplementation was 91.8 fL.
Three patients had renal insufficiency as the likely cause for their anemia, with serum Cr values between 3.0 mg/dL and 5.4 mg/dL. Three patients had well-documented autoimmune hemolytic anemia with a positive direct antibody test; B 12 levels ranged between 143 pg/mL and 177 pg/mL, and all three had an elevated MCV due to reticulocytosis. Another patient had a spuriously high MCV of 122.8 fL due to cold agglutinin disease; his MCV data were deleted from the statistical analysis and table 3. Two patients likely had a myelodysplastic syndrome (MDS) explaining their macrocytic anemia. Two patients were diagnosed with plasma cell myeloma within 2 months after starting B 12 therapy. Folate testing, either serum folate or red cell folate, was done in a small minority of patients in this study, and only one patient was identified with possible deficiency. This woman, age 91 years, had a slightly low serum folate level of 3.6 ng/ mL (reference range 4-20 ng/mL), and baseline values were B 12 86 pg/mL, Hgb 11.6 g/dL, and MCV 98.2 fL with no follow-up labs. Her decreased sensation below the knees bilaterally was unchanged with B 12 and folate supplementation.
In five patients, drugs may have been the cause of borderline to mild macrocytosis (MCV ≥96.1 fL) without anemia. The implicated drugs were chemotherapeutic agents in two, phenytoin in one, both phenytoin and methotrexate in one, and hydroxyurea in one. No patients were identified in which hypersegmented neutrophils were reported in the electronic medical record within 6 months before initiating intramuscular vitamin B 12 supplementation.
Discussion
The elderly age distribution and female predominance were expected given the demographics of vitamin B 12 deficiency. Also, some of the female predominance may be attributable to the higher frequency of gastric bypass surgery in women; 20 of 24 such patients were women.
The positive correlation between serum MMA and renal function is well known. 10 Caution is advised in interpreting serum MMA levels in patients with renal insufficiency (eg, Cr >1.6 mg/dL). In one study from the United Kingdom, average MMA levels increased from 0.25 mmol/L in people age 65 years to 74 years, to 0.38 mmol/L in people >85 years. 11 Declining renal function and slightly lower B 12 levels only partially accounted for this change. Elevated serum Hcy is another metabolite indicator of B 12 deficiency but is less specific than MMA, and there are not well established diagnostic cutoffs. Like B 12 , Hcy is largely cleared by the kidneys, and levels are higher in patients with renal insufficiency. 12 How to manage patients with a history of gastrointestinal surgery is unclear. This study could not evaluate the frequency with which low vitamin B 12 levels are encountered in this patient cohort, but it seems fairly common. Notably, these patients rarely have any meaningful clinical response to parenteral vitamin B 12 supplementation. Some might argue that a low threshold for B 12 therapy is reasonable as a preventative measure, rather than waiting for symptomatic deficiency to develop. 1 This issue deserves further study, particularly with the recent increase in gastric procedures for morbid obesity.
The quagmire surrounding vitamin B 12 deficiency contrasts sharply with iron deficiency, which is much more common, readily confirmed by laboratory testing, and predictably responsive to supplementation. Notably, iron deficiency was nearly as common as B 12 deficiency in this cohort of patients started on B 12 injections. The rarity of folate deficiency is consistent with recent data from the United States and Canada, pointing to the introduction of widespread folic acid fortification of many foods. 13, 14 Hematologists and hematopathologists frequently encounter patients with low B 12 levels that are found to have another cause for their macrocytosis with or without anemia (eg, hemolysis with reticulocytosis, drug-related macrocytosis, MDS, or other neoplasms). Incorrectly attributing a macrocytic anemia to B 12 deficiency delays further evaluation that could uncover the true underlying cause, and of course, appropriate treatment is delayed as well. Myelodysplastic syndromes, particularly 5q syndrome, often present with a macrocytic anemia. The medical records of 13 patients (not included in the 192 patient cohort) with MDS diagnosed at Marshfield Clinic in which cytogenetics revealed a 5q deletion (accompanied by noncomplex cytogenetic abnormalities in two) were reviewed. All 11 of the patients tested at baseline had a normal serum B 12 level >250 pg/mL. Although these data suggest that low serum B 12 levels are uncommon in patients with MDS, one author (GRS) has anecdotally encountered several MDS patients with low B 12 levels that were unresponsive to supplementation. Further testing for MMA could clarify the situation in most cases.
The dramatic presentation and response of patients with fullblown vitamin B 12 deficiency provides some insight into recognizing diagnostic pitfalls. Two recent cases of pernicious anemia encountered by one author (GRS) during the preparation of this manuscript serve as examples. Both patients had baseline B 12 levels <50 pg/mL, positive intrinsic factor (IF) antibodies, and severe macrocytic anemia (Hgb <5.8 g/dL and MCV >134.5 fL) with striking poikilocytosis that morphologically raised some concern for an MDS (possibly with myelofibrosis). In the one patient tested, MMA was 32.8 µmol/L and Hcy 94.9 µmol/L. Both patients had tremendous elevations in their lactate dehydrogenase level (>2600 U/L) and slight to moderately increased indirect bilirubin, which raised consideration of a hemolytic anemia. In fact, one patient had a positive direct antiglobulin test (albeit weak reactivity) and an increased reticulocyte count (but not nearly enough to explain the severe macrocytosis). The other patient had a low haptoglobin level. Within 3 weeks of starting parenteral B 12 therapy, Hgb and MCV of both patients had normalized (>12.2 g/dL and <97.3 fL, respectively).
In the electronic medical record, the reporting of hypersegmented neutrophils was of no help in diagnosing vitamin B 12 deficiency. This concurs with most reports in the literature stating that the presence of hypersegmented neutrophils on the peripheral blood smear is neither sensitive nor specific for this purpose. 15 However, careful review of a peripheral blood smear by a hematologist or hematopathologist may provide helpful clues regarding the underlying cause of a macrocytic anemia.
Approximately 75% of serum B 12 is bound to haptocorrin (formerly called transcobalamin I) whose function is unknown. 9 Therefore, total serum B 12 levels largely reflect B 12 that is not bioavailable. Total transcobalamin, consisting of holoTC and apo-transcobalamin, is the major carrier protein in the plasma/serum that delivers B 12 to the tissues. Conceptually, holoTC should more accurately reflect intracellular B 12 levels. Sequencing of the TCN1 gene for haptocorrin has identified a 999G>T polymorphism with heterozygosity in about 12% of individuals of European ancestry. 16 Based on limited familial studies, heterozygosity for this polymorphism is associated with slightly lower total haptocorrin and, hence, slightly lower total serum B 12 levels. This polymorphism may help explain why whites, on average, have lower total haptocorrin and B 12 levels than blacks. A 776C>G polymorphism in the transcobalamin gene (TCN2) that affects holoTC has been described as commonly occurring in the Portuguese population. 17 Extremely rare mutations in the TCN2 gene may result in severe intracellular cobalamin depletion. 18 More work needs to be done to sort out the genetics and pathophysiology related to cobalamin deficiency. 19 Some, but not all, studies have found marginally better performance (as assessed by receiver operator curves) by holoTC when compared with serum B 12 .
9,20-22 However, the "gold standards" for classifying patients as B 12 deficient have been dubious (ie, elevated MMA or Hcy, with minimal or no clinical correlation). One study used red blood cell (RBC) cobalamin as the "gold standard" and found that holoTC slightly outperformed B 12 . Curiously, techniques to measure RBC cobalamin were reported four decades ago and yet are still not widely available. Rare patients with pernicious anemia have spurious elevations of vitamin B 12 when using methods based on competitive binding of serum B 12 with reagent intrinsic factor. 23 A recent National Health and Nutrition Examination Survey (NHANES) roundtable recommended conventional serum B 12 over holoTC at this time, since holoTC methods are relatively new and would benefit from additional performance studies. 24 Furthermore, the same roundtable summary expressed caution regarding the common assumption that detecting subclinical deficiency early is important to enable public health interventions that prevent its progression to clinical deficiency. These experts questioned the value of further hypothesis generating epidemiologic studies and stated that prospective clinical trials are urgently needed. 8, 25, 26 From a cost-effective public health standpoint, some might advocate widespread oral vitamin B 12 supplementation without laboratory testing to provide insurance against subclinical B 12 deficiency. 27 Although the general public and commercial health food suppliers have a seemingly insatiable appetite for "fountain of youth" dietary supplements, it seems premature to recommend mandatory fortification of the food supply without well-conducted, randomized clinical trials. Several patients in the current study were given vitamin B 12 injections solely at their request, and sometimes for psychological benefit; patient education would seem more appropriate.
In terms of future studies, a relatively small, well designed, prospective clinical trial may be enlightening. Patients could initially be identified by laboratory testing (eg, a cohort of patients with serum B 12 levels of <200 pg/mL). A comprehensive battery of laboratory tests could be obtained both at baseline and, with the exception of genetic tests, at defined intervals once treatment had been initiated (eg, MMA, Hcy, holoTC, a full CBC, IF antibodies, ferritin, serum iron/total iron binding capacity, serum folate, RBC folate, and sequencing of the TCN1 and TCN2 genes). For study purposes, perhaps the Schilling test could even be resurrected to better understand the absorption issues. A careful neurologic exam would be documented by a neurologist and repeated at prescribed intervals. Treatment would be standardized.
This retrospective study has several limitations. Patients were selected on the basis of clinical initiation of intramuscular B 12 treatment. Thus, this was not a random or representative sample of the general population. Laboratory testing before initiation of therapy was inconsistent, and monitoring even more inconsistent. Also, there was no standard treatment protocol, and numerous patients were incompletely treated; either they or their provider discontinued the therapy. In patients deemed to have had a laboratory response to B 12 supplementation, there was no control group of untreated or placebo-treated patients, so the possibility that high MCV values decreased because of regression toward the mean cannot be ruled out. It was difficult during chart review to capture all confounding variables (eg, not having stable baseline or follow-up CBC data). This could be due to blood loss, medication changes, or other alterations in clinical status. Comprehensive neurologic exams were rarely conducted, so there may have been some patients with small objective improvements that were overlooked. This data may be considered somewhat dated; however, there have been no significant changes in B 12 testing over the past decade.
In summary, of 192 patients started on intramuscular B 12 injections, only 35 (18.3%) had laboratory evidence supporting "probable" or "confirmed" deficiency. Furthermore, only 18 patients (9.4%) had data supportive of a clinical response. In these 18 patients, the baseline serum B 12 level was ≤107 pg/mL; only three had a baseline MMA level, which was ≥1.29 μmol/L for all three. In terms of diagnosing clinically evident vitamin B 12 deficiency with a reasonable expectation of clinical response, these limited data suggest that current diagnostic algorithms could be modified to increase specificity without sacrificing sensitivity. Additional studies are needed to corroborate these findings and further explore the benefit (if any) in detecting and treating "subclinical" vitamin B 12 deficiency.
The following are offered as practical suggestions that providers and laboratories may find useful. 
